UCB Reports P-III (BE BOLD) Trial Data on Bimzelx in Active Psoriatic Arthritis

Why It Matters

The data positions Bimzelx as a potentially more effective option for psoriatic arthritis, which could shift prescribing patterns and influence future treatment guidelines. Superior efficacy may also strengthen UCB’s market position against established biologics like Skyrizi.

Key Takeaways

• Bimzelx achieved 49.1% ACR50 vs 38.4% Skyrizi.
• Week‑4 ACR50 response: 19.9% vs 7.2%.
• Combined ACR50+PASI100 at week 16: 33.5% vs 24.4%.
• MDA higher (43% vs 39.9%) but not statistically significant.
• Exploratory endpoints favor Bimzelx; data to EULAR 2026.

Pulse Analysis

Psoriatic arthritis (PsA) remains a therapeutic challenge, with patients often cycling through multiple biologics to achieve disease control. Bimzelx, a dual IL‑17A/F inhibitor, offers a broader cytokine blockade than the IL‑23‑targeted Skyrizi, potentially explaining its stronger clinical signals. The BE BOLD trial, enrolling over 550 participants across diverse geographic sites, provides a head‑to‑head comparison that is rare in the biologics arena, giving clinicians a clearer efficacy benchmark.

The trial’s primary endpoint—ACR50 at week 16—was met with a 10‑point advantage for Bimzelx, underscoring its rapid and robust anti‑inflammatory effect. Notably, patients on Bimzelx reached ACR50 as early as week 4, a timeline that could translate into faster symptom relief and functional improvement. While the MDA secondary endpoint fell short of statistical significance, the consistent trend across other measures, including PASI100 and DAPSA low disease activity, reinforces the drug’s overall potency. These findings are likely to be scrutinized at the upcoming EULAR 2026 congress, where detailed subgroup analyses will further inform therapeutic decision‑making.

From a commercial perspective, the results could reshape the PsA market, where Skyrizi currently commands a sizable share. UCB’s ability to demonstrate superiority may accelerate regulatory submissions and bolster payer negotiations, especially as the acquisition of Candid Therapeutics for roughly $2.2 billion signals the company’s commitment to expanding its immunology portfolio. If Bimzelx secures favorable labeling and reimbursement, it could become a preferred first‑line biologic, prompting competitors to revisit dosing strategies or develop next‑generation IL‑17 inhibitors to maintain relevance.